BRL 303 Enters a China Rare Disease Development Pilot

Company BRL Medicine (Shanghai BRL Medicine) Event Type Regulatory pilot inclusion (China CDE) and trial clearance disclosure Modality Allogeneic CD19 CAR-T (healthy-donor, gene-modified) Asset BRL-303 (TyU19) Target CD19 Disease Area Refractory systemic sclerosis; refractory lupus (Phase I) Summary China’s Center for Drug Evaluation included BRL…